Showing results (301-310 of 375) with videos related to

Sort By:
Pageof 38
Investigational New Drugs|February 1, 1990
A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphomaH B Muss, N Spell, D Scudiery, et al.
American Journal of Clinical Oncology|October 1, 1983
Vincristine by continuous infusion in refractory breast cancer: a phase II studyJ O Hopkins, D V Jackson, D R White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1990
High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology AssociationH B Muss, L D Case, R L Capizzi, et al.
American Journal of Clinical Oncology|October 1, 1985
Cytotoxic chemotherapy and androgen priming in patients with advanced carcinoma of the prostate. A phase II trial of the Piedmont Oncology AssociationH B Muss, D Case, M R Cooper, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
Effects of Genetically-Proxied Antihypertensive Drug Targets on Preeclampsia and Birth WeightMaddalena Ardissino, Alec P Morley, Eleanor M F Richards, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|July 16, 2013
Wave packet spreading and localization in electron-nuclear scatteringPaul E Grabowski, Andreas Markmann, Igor V Morozov, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|May 25, 2012
A standards-based, peer-reviewed teaching award to enhance a medical school's teaching environment and inform the promotions processNancy S Searle, Cayla R Teal, Boyd F Richards, et al.
American Journal of Clinical Oncology|June 1, 1984
The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II studyP C Amrein, R F Poulin, M Coleman, et al.
American Journal of Clinical Oncology|June 1, 1983
Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213D V Jackson, H B Wells, D R White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1986
Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology AssociationF Richards, L D Case, D R White, et al.
Pageof 38